A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

Investigational New Drugs

Volumn 24, Issue 4, 2006, Pages 353-357

  Ajani, Jaffer A ^a,b   Jiang, Yixing ^a,b,c   Faust, Josephine ^a   Chang, Baochong B ^a,b   Ho, Linus ^a,b   Yao, James C ^a,b   Rousey, Steven ^a,b   Dakhil, Shaker ^a,b   Cherny, Richard C ^a,b   Craig, Catherine ^a,b   Bleyer, Archie ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Bryostatin 1; Gastric or gastroesophageal adenocarcinoma; Protein Kinase C

Indexed keywords

BRYOSTATIN 1; NARCOTIC ANALGESIC AGENT; NSC 339555; PACLITAXEL; PHORBOL ESTER; PROTEIN KINASE C;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; HISTOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRYOSTATINS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MACROLIDES; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 33646501280     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-6452-1     Document Type: Article

References (16)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Spitaler M, Cantrell DA (2004) Protein kinase C and beyond. Nat Immunol 5:785-790
3. Blumberg PM (1988) Protein kinase C as the receptor for the phorbo ester tumor promoters: Sixth Rhoades memorial award lecture. Cancer Res 48:1-8
4. Hofmann J (2004) Protein kinase C isoenzymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 4:125-146
5. Pettit GR, Herald CL, Doubet DL, et al (1982) Isolation and structure of bryostatin-1. J Am Chem Soc 104:6846-6848
6. Gschwendt M, Furstenberger G, Rose-John S, et al (1988) Bryostatin-1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. Carcinogenesis 9:555-562
7. Hennings H, Blumberg PM, Pettit GR, et al (1987) Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 8:1343-1346
8. Schuchter LM, Esa AH, May S, et al (1991) Successful treatment of murine melanoma with bryostatin-1. Cancer Res 51:682-687
9. Hornung RL, Pearson JW, Beckwith M, et al (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101-107
10. Jones RJ, Sharkis SJ, Miller CB, et al (1990) Bryostatin-1, a unique biologic response modifier: Anti-leukemic activity in vitro. Blood 75:1319-1323
11. Mohammad RM, Diwakaran H, Maki A, et al (1995) Bryostatin-1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 19:667-673
12. Grant S, Jarvis WD, Swerdlow PS, et al (1992) Potentiation of the activity of 1-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin-1 in HL-60 cells: association with enhanced fragmentation of mature DNA. Cancer Res 52:6270-6278
13. Koutcher JA, Motwani M, Zakian KL, et al (2000) The in vitro effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res 6:1498-1507
14. Ajani JA, Fairweather J, Dumas P, et al (1998) Phase II study of Taxol in patients with advacd gastric carcinoma. Cancer J Sci Am 4:269-274
15. Asiedu C, Biggs J, Lilly M, Kraft AS (1995) Inhibition of lleukemic cell growth by the protein kinase C activator bryostatin-1 correlates with the dephosphorylation of cyclin dependent kinase 2. Cancer Res 55:3716-3720
16. Kaubisch A, Kelsen DP, Saltz L, Kemeny N, O'Reilly E, Ilson D, Endres S, Barazzuol J, Schwartz GK (1999) A phase I trial of weekly sequential bryostatin-1 (BRYO) and paclitaxel in patients with advanced solid tumors. Proc Amer Soc Clin One 18:166a